highli
conserv
noncod
rna
ncrna
element
viral
genom
transcript
offer
new
opportun
expand
repertoir
drug
target
develop
antiinfect
therapi
ligand
bind
ncrna
architectur
abl
affect
interact
structur
stabil
conform
chang
therebi
block
process
essenti
viral
replic
proof
concept
target
function
rna
small
molecul
inhibitor
demonstr
multipl
virus
rna
genom
strategi
identifi
antivir
compound
inhibitor
ncrna
increasingli
emphas
consider
druglik
properti
candid
molecul
emerg
screen
ligand
design
recent
effort
antivir
lead
discoveri
rna
target
provid
druglik
small
molecul
inhibit
viral
replic
includ
inhibitor
human
immunodefici
viru
hiv
hepat
c
viru
hcv
sever
respiratori
syndrom
coronaviru
sar
cov
influenza
viru
target
select
remain
challeng
discoveri
use
rnabind
compound
better
understand
emerg
properti
defin
rna
target
amen
inhibit
small
molecul
ligand
insight
success
approach
target
viral
ncrna
hiv
hcv
sar
cov
influenza
provid
basi
futur
explor
rna
target
therapeut
intervent
viral
pathogen
creat
urgent
unmet
medic
need
virus
target
ncrna
compon
genom
transcript
may
promis
includ
insectborn
flavivirus
dengu
zika
west
nile
filovirus
ebola
marburg
w
hile
larg
major
approv
drug
act
protein
target
chemic
divers
set
clinic
import
antibiot
bind
select
rna
compon
rrna
bacteri
ribosom
therebi
interfer
protein
synthesi
antibiot
deriv
natur
product
provid
paradigm
target
structur
noncod
rna
approach
therapeut
intervent
noncod
rna
ncrna
molecul
increasingli
recogn
key
regulatori
player
biolog
process
particip
base
threedimension
structur
rather
sequenc
welldefin
structur
ncrna
fold
provid
potenti
uniqu
interact
site
select
smallmolecul
ligand
affect
rna
biolog
function
outsid
bacteri
ribosom
untransl
rna
region
drug
target
pursu
discov
therapeut
viral
infect
includ
caus
human
immunodefici
viru
hiv
hepat
c
viru
hcv
pathogen
singlestrand
rna
genom
includ
structur
noncod
region
play
key
role
viral
infect
cycl
harbor
potenti
bind
site
small
molecul
inhibitor
high
conserv
untransl
region
viral
genom
along
absenc
homolog
host
cell
rna
render
structur
viral
regulatori
rna
attract
target
develop
novel
antiinfect
drug
unlik
typic
inhibitor
bind
pocket
protein
site
ligand
recognit
rna
often
shallow
highli
solvat
conform
flexibl
therefor
structur
physicochem
properti
small
molecul
ligand
rna
differ
markedli
drug
target
protein
clinic
use
rnabind
antibiot
deriv
natur
product
averag
structur
complex
hydrophil
contain
larger
number
hydrogen
bond
donor
compar
druglik
compound
molecular
properti
creat
challeng
reconcil
design
optim
rnabind
ligand
druglik
featur
affect
absorpt
distribut
vivo
strategi
design
discoveri
rnabind
ligand
outlin
long
rise
ncrna
comprehens
review
target
rna
small
molecul
publish
regularli
last
year
among
chemic
divers
class
rna
binder
recur
scaffold
found
among
deriv
aminoglycosid
planar
intercal
includ
acridin
phenothiazin
figur
aminoglycosid
natur
product
streptomyc
soil
bacteria
bind
ribosom
decod
site
exert
antibiot
activ
interf
bacteri
protein
synthesi
amin
function
group
aminoglycosid
proton
physiolog
condit
result
overal
cation
charg
promot
nucleic
acid
bind
hamper
cell
penetr
aminoglycosid
semisynthet
deriv
report
promiscu
bind
numer
ncrna
target
includ
regulatori
element
hiv
two
decad
ago
first
viral
rna
investig
smallmolecul
inhibit
suggest
aminoglycosid
bind
rna
fold
structur
electrostat
complementar
wherebi
posit
charg
ammonium
group
ligand
recogn
metalionbind
pocket
creat
rna
architectur
similarli
promiscu
bind
structur
rna
observ
intercal
compound
contain
flat
aromat
scaffold
acridin
phenazin
phenothiazin
deriv
earli
ligandbind
studi
ncrna
focus
proof
concept
often
involv
promiscu
binder
includ
aminoglycosid
intercal
recent
consider
compound
druglik
promin
includ
rna
target
effort
rnabind
drug
oxazolidinon
antibiot
provid
compel
remind
properti
benefici
rnatarget
druglik
may
reconcil
within
small
molecul
compound
figur
focu
progress
last
year
discoveri
investig
small
molecul
ligand
viral
rna
target
emphasi
given
ligand
molecular
weight
coverag
literatur
occasion
go
back
time
previous
report
compound
class
recent
work
reveal
new
find
mechan
action
provid
structur
insight
review
recent
discov
ligand
target
viral
rna
includ
discuss
compound
physicochem
properti
affect
druglik
long
known
interfer
translat
compound
provid
power
tool
elucid
ribosom
function
decad
mount
evid
ribosomeinhibit
antibiot
target
rna
compon
rrna
moaz
noller
demonstr
sever
class
antibiot
bind
directli
rrna
observ
spur
effort
academia
pharmaceut
industri
discov
small
molecul
ligand
structur
rna
hiv
transactiv
respons
tar
rev
respons
rre
rna
first
viral
regulatori
element
shown
bind
small
molecul
compound
interf
key
step
hiv
infect
realiz
repertoir
therapeut
approach
combat
infect
may
expand
inhibitor
target
viral
rna
compon
quickli
gave
birth
notion
rna
emerg
drug
target
sinc
intervent
small
molecul
bind
ncrna
element
explor
sever
virus
tabl
hiv
remain
intens
studi
viru
multipl
function
rna
structur
genom
besid
tar
rre
site
investig
target
small
molecul
ligand
includ
dimer
initi
sequenc
di
packag
signal
gagpol
frameshift
signal
previou
review
includ
comprehens
articl
le
grice
cover
literatur
effort
target
hiv
rna
year
recent
studi
discoveri
inhibitor
target
tar
rre
rna
screen
scaffoldbas
design
discuss
follow
section
figur
tabl
like
hiv
hcv
carri
singlestrand
rna
genom
revers
transcrib
directli
serv
code
mrna
viral
protein
translat
hcv
genom
driven
structur
rna
element
untransl
region
utr
serv
intern
ribosom
entri
site
ire
subdomain
hcv
ire
function
conform
switch
identifi
target
site
small
molecul
inhibitor
captur
extend
conform
rna
therebi
block
viral
translat
previou
review
dibrov
et
al
describ
discoveri
hcv
iresdirect
inhibitor
structur
well
mechanismofact
studi
establish
conform
switch
motif
privileg
target
site
antivir
rnabind
review
box
clogp
calcul
logarithm
partit
coeffici
noctanol
water
measur
compound
hydrophil
low
hydrophil
indic
high
log
p
valu
valu
implic
poor
cell
membran
permeat
absorpt
psa
polar
surfac
area
calcul
molecular
surfac
creat
polar
atom
primarili
oxygen
nitrogen
includ
attach
hydrogen
atom
psa
caus
poor
cell
membran
permeat
hbd
number
hydrogen
bond
donor
primarili
hydrogen
link
oxygen
nitrogen
atom
hydrogen
bond
donor
improv
solubl
water
imped
cell
membran
permeat
major
approv
drug
contain
hbd
median
ba
bioavail
experiment
determin
fraction
nonintraven
administ
drug
dose
reach
system
circul
outlin
recent
progress
develop
translat
inhibitor
target
hcv
ire
figur
tabl
viral
ncrna
target
small
molecul
ligand
emerg
recent
review
previous
frameshift
pseudoknot
pk
genom
sar
coronaviru
cov
promot
viral
rnadepend
rna
polymeras
ssrna
genom
influenza
viru
ligand
discoveri
effort
structur
studi
target
discuss
figur
tabl
singlestrand
rna
genom
hiv
contain
multipl
regulatori
element
involv
transcript
regul
revers
transcript
viral
protein
translat
nucleocytoplasm
transport
genom
dimer
virion
packag
tar
element
resid
within
first
nucleotid
viral
genom
serv
bind
site
tat
protein
format
tattar
complex
stimul
transcript
elong
yield
fulllength
transcript
complex
mechan
also
involv
host
cell
factor
tatbind
site
tar
consist
conserv
rna
stemloop
pyrimidinerich
bulg
figur
tabl
ligand
shown
yellow
stick
represent
posit
two
magnesium
ion
indic
green
sphere
c
target
recognit
hydrogen
bond
partial
intercal
benzimidazol
subdomain
iia
rna
complex
crystal
structur
structur
imag
prepar
pdb
coordin
file
conform
dynam
adopt
stabl
order
structur
complex
tat
peptid
small
molecul
ligand
disrupt
tattar
complex
compet
ligand
bind
rna
target
block
effici
hiv
replic
recogn
earli
potenti
path
develop
antivir
drug
numer
studi
focus
discoveri
design
tar
rnabind
inhibitor
includ
peptid
natur
product
aminoglycosid
synthet
small
molecul
earlier
effort
summar
sever
excel
review
recent
schneekloth
cowork
appli
small
molecul
microarray
smm
screen
fluoresc
label
tar
hairpin
model
oligonucleotid
identifi
select
binder
similar
approach
taken
disney
seeberg
explor
interact
aminoglycosid
ribosom
asit
group
intron
ribozym
rna
recent
studi
hiv
tar
microarrayimmobil
screen
librari
compos
druglik
small
molecul
bias
chemotyp
consid
promot
rna
bind
counterscreen
appli
unrel
rna
hairpin
exclud
promiscu
binder
smm
screen
return
low
hit
rate
excel
low
falseposit
rate
eventu
deliv
confirm
hit
compound
tabl
reason
druglik
properti
antihiv
activ
tlymphoblast
ec
valu
well
low
cytotox
thienopyridin
deriv
surprisingli
hydrophob
rnabind
ligand
similar
chemotyp
report
tarbind
remain
seen
potenc
thienopyridin
deriv
tabl
ligand
shown
yellow
stick
represent
ad
tetraloop
indic
gray
c
detail
view
ligand
bind
site
nmr
model
show
hydrogen
atom
ligand
structur
imag
prepar
pdb
coordin
file
improv
furnish
lead
candid
develop
antivir
drug
target
hiv
tar
nevertheless
smm
screen
approach
proven
promis
method
discoveri
druglik
ligand
rna
fruit
applic
ncrna
target
expect
fragmentbas
screen
approach
identifi
ligand
hiv
tar
element
describ
colleagu
interrog
set
small
molecul
select
repres
molecular
motif
benefici
rna
recognit
fragment
rich
chemotyp
provid
hydrogen
bond
donor
includ
amin
amidin
guanidin
well
benzen
ring
stack
interact
fluorimetr
competit
assay
box
use
determin
ligand
bind
test
abil
compound
displac
dyelabel
tat
peptid
tar
model
rna
seven
small
molecul
screen
set
found
compet
tat
peptid
bind
tar
ic
valu
includ
quinazolin
shown
exampl
tabl
ic
valu
least
two
hit
compound
identifi
previous
inhibitor
tattar
complex
format
shown
downregul
tat
transactiv
cellbas
assay
cellular
activ
test
fragment
screen
approach
report
et
al
onedimension
h
nmr
use
confirm
ligand
interact
rna
target
monitor
chang
iminoproton
signal
upon
titrat
compound
consequ
composit
bia
screen
set
small
molecul
rich
hydrogen
bond
donor
hit
compound
tend
exceed
number
hydrogen
bond
donor
typic
druglik
molecul
howev
fragment
incorpor
construct
larger
ligand
futur
would
reduc
number
hydrogen
bond
donor
site
benhida
cowork
pursu
design
approach
tar
rnabind
ligand
base
aminophenylthiazol
deriv
nucleobas
analog
propos
interact
au
pair
hydrogen
bond
aminothiazol
scaffold
hoogsteen
edg
adenin
set
conjug
aminophenylthiazol
scaffold
term
nucleobas
highlight
blue
compound
tabl
differ
natur
amino
acid
dipeptid
synthes
test
rna
target
bind
well
antivir
activ
cell
cultur
consequ
design
paradigm
focus
scaffold
nucleobaselik
interact
result
compound
hydrophil
carri
larger
number
hydrogen
bond
donor
group
ligand
tar
element
identifi
monitor
fluoresc
chang
upon
compound
titrat
termin
dyelabel
tar
model
oligonucleotid
box
nucleobas
conjug
arginin
lysin
histidin
found
tightli
bind
tar
rna
howev
histidin
deriv
tabl
select
tar
binder
k
whose
affin
target
diminish
presenc
nucleic
acid
arginin
lysin
conjug
show
better
interact
tar
rna
k
respect
bind
promiscu
strongli
affect
presenc
competitor
nucleic
acid
perhap
attest
correl
target
select
biolog
activ
histidin
deriv
show
antivir
activ
hivinfect
human
cell
ic
clear
viral
inhibit
potenc
exce
target
bind
affin
find
suggest
howev
compound
may
act
target
addit
tar
rna
among
recent
describ
structur
complex
ligand
tar
rna
whose
molecular
weight
exce
aminoglycosidebenzimidazol
conjug
develop
arya
appella
cowork
nucleobaselink
aminoglycosid
synthes
hamasaki
colleagu
aminoglycosid
conjug
seri
highli
hydrophil
compound
contain
hydrogen
bond
donor
nanomolar
affin
tar
target
antivir
activ
conjug
compound
cell
report
hiv
rre
element
locat
within
stretch
approxim
nucleotid
second
intron
viral
genom
rna
complex
structur
tar
motif
stemloop
iib
sliib
form
residu
rre
figur
serv
highaffin
bind
site
viral
rev
protein
rev
bind
rre
requir
nucleocytoplasm
export
fulllength
singli
splice
viral
transcript
disrupt
revrr
interact
explor
two
decad
strategi
develop
antivir
therapi
past
effort
discov
revcompetitor
ligand
rre
rna
larg
focus
ligandbas
design
summar
comprehens
review
two
studi
publish
small
molecul
highthroughput
screen
inhibitor
target
revrr
complex
none
approach
yet
produc
bona
fide
inhibitor
vitro
revrr
complex
format
show
antivir
activ
cell
recent
studi
rana
colleagu
shown
posttranscript
modif
rre
adenin
base
sliib
play
critic
role
activ
rrerev
complex
serv
poignant
remind
authent
model
system
requisit
studi
rna
target
gallego
cowork
identifi
inhibitor
hiv
rna
biogenesi
block
revrr
interact
bind
competit
screen
box
fdaapprov
drug
complex
format
fluoresc
label
rev
peptid
rre
sliib
rna
target
antivir
activ
hit
compound
cell
confirm
box
termin
target
label
assay
reli
assumpt
ligand
bind
result
chang
rna
conform
dynam
therebi
translat
dosedepend
fluoresc
chang
dye
termin
conjug
target
oligonucleotid
unlik
ligand
competit
assay
test
termin
label
oligonucleotid
model
usual
resolv
bind
site
competit
label
tool
ligand
assay
monitor
displac
fluoresc
label
tool
ligand
specif
bind
site
rna
target
depend
target
tool
ligand
may
small
molecul
peptid
protein
nucleic
acid
implement
good
understand
competit
kinet
requir
tool
ligand
slow
offrat
may
requir
long
incub
time
dynam
rang
detect
compound
affin
limit
affin
tool
ligand
may
challeng
identifi
weak
binder
incorpor
fluoresc
nucleosid
analog
assay
reli
monitor
fluoresc
chang
origin
chang
rna
conform
dynam
direct
quench
upon
ligand
bind
model
oligonucleotid
carri
fluoresc
nucleobas
incorpor
proxim
specif
bind
site
direct
inform
bind
site
specif
obtain
modif
target
incorpor
chemic
modifi
nucleosid
analog
concern
fret
reson
energi
transfer
assay
use
rna
target
label
pair
fret
dye
effici
fret
effect
depend
sixth
order
distanc
donor
acceptor
provid
sensit
measur
ligandinduc
conform
chang
rna
target
clomiphen
tabl
cyproheptadin
inhibit
hiv
transcript
affect
level
splice
versu
unsplic
viral
transcript
extent
consist
abil
disrupt
revrr
complex
function
vitro
clomiphen
select
estrogen
receptor
modul
inhibit
rev
peptid
bind
rre
sliib
ic
valu
antivir
activ
ec
valu
cellbas
assay
correspond
valu
cyproheptadin
antihistamin
receptor
antagonist
ic
ec
interact
clomiphen
highli
specif
rre
sliib
target
target
bind
cyproheptadin
significantli
compromis
presenc
competitor
trna
dna
nmr
spectroscop
studi
reveal
grich
intern
loop
lower
stem
sliib
interact
site
overlap
bind
region
rev
consist
propos
mechan
inhibit
ligand
competit
direct
interact
hydrophob
drug
rna
target
may
appear
unexpect
dispel
notion
larg
number
heteroatom
hydrogen
bond
donor
acceptor
requir
confer
rnafriendli
properti
small
molecul
ligand
hydrogen
bond
donor
absent
either
compound
translat
hcv
genom
rna
driven
ire
element
recruit
ribosom
directli
viral
start
codon
without
need
host
cell
initi
factor
uniqu
role
viral
ire
high
conserv
clinic
isol
led
recognit
ncrna
potenti
drug
target
high
throughput
screen
compound
inhibit
ire
function
cellbas
report
translat
assay
led
discoveri
phenazin
deriv
biaryl
guanidin
moder
select
viral
translat
target
structur
compound
chemic
seri
suggest
may
interact
ire
rna
target
bind
antivir
activ
report
earli
studi
import
breakthrough
achiev
seth
colleagu
use
mass
spectrometrybas
screen
compound
identifi
deriv
ligand
bind
intern
loop
rna
subdomain
iia
hcv
ire
figur
lead
optim
driven
structureact
relationship
data
furnish
compound
tabl
affin
k
ire
target
determin
mass
spectrometri
inhibit
hcv
cell
cultur
ec
valu
show
cytotox
concentr
mechan
action
studi
reveal
compound
act
alloster
inhibitor
rna
conform
switch
ire
subdomain
iia
contrast
metabolitesens
riboswitch
hcv
ire
subdomain
iia
motif
repres
new
class
rna
conform
switch
structur
welldefin
ligandfre
bound
state
may
repres
simplest
form
ligandrespons
pure
mechan
switch
nucleic
acid
synthet
benzimidazol
fortuit
ligand
recognit
site
guanosin
captur
subdomain
iia
target
extend
conform
block
viral
translat
initi
ire
element
xray
crystallographi
provid
structur
insight
conform
state
subdomain
iia
switch
absenc
presenc
inhibitor
ligand
extend
conform
switch
bound
inhibitor
encapsul
deep
solventexclud
rna
pocket
resembl
ligand
interact
site
aptam
riboswitch
figur
b
c
depth
structur
complex
physicochem
properti
ligand
bind
pocket
distinguish
ire
iia
switch
viral
rna
target
suggest
discoveri
druglik
inhibitor
feasibl
fretbas
assay
box
develop
investig
ligand
bind
subdomain
iia
screen
viral
translat
inhibitor
captur
rna
switch
extend
state
differ
assay
monitor
fluoresc
chang
nucleosid
analog
box
incorpor
intern
loop
subdomain
iia
diaminopiperidin
compound
tabl
found
bind
ire
target
well
unlik
diaminopiperidin
ligand
lock
rna
conform
switch
bent
state
therebi
inhibit
viral
translat
initi
recent
review
summar
comprehens
studi
diaminopiperidin
hcv
translat
inhibitor
diaminopiperidin
hydrophil
compound
contain
numer
hydrogen
bond
donor
suggest
polar
interact
play
import
role
rna
target
recognit
consequ
bind
affin
compound
subdomain
iia
rna
target
decreas
ionic
strength
medium
contrast
inhibitor
druglik
properti
contain
basic
amino
group
posit
charg
physiolog
condit
moreov
construct
pyran
ring
opinion
wireswileycomrna
requir
lengthi
synthet
rout
hamper
deep
explor
chemic
seri
recent
design
second
gener
ligand
guanosin
bind
pocket
hcv
ire
subdomain
iia
target
address
shortcom
origin
deriv
approach
maintain
nonplanar
benzimidazol
ligand
introduc
sp
carbon
center
pyran
ring
ligand
design
aryl
deriv
repres
compound
steric
hindranc
aryl
substitu
induc
twist
conform
overal
nonplanar
shape
result
compound
anoth
set
analog
replac
basic
imidazol
ring
first
gener
ligand
less
basic
oxazol
system
result
ligand
exemplifi
compound
access
straightforward
synthet
rout
display
good
druglik
properti
howev
none
synthes
aryl
benzimidazol
howev
synthesi
test
silico
design
compound
report
structur
plastic
hcv
ire
subdomain
iia
illustr
challeng
face
comput
approach
rna
target
gener
larg
conform
chang
iia
rna
target
upon
ligand
bind
accompani
extens
rearrang
base
stack
unexpect
like
beyond
predict
abil
current
comput
approach
rel
success
md
studi
reproduc
conform
rearrang
benzimidazol
ligand
bind
iia
rna
may
attribut
fact
experiment
waypoint
form
highresolut
crystal
structur
avail
guid
calcul
challeng
larg
conform
chang
rna
target
compound
domin
electrostat
interact
anion
polym
concurr
impact
counterion
bind
hydrat
recogn
achil
heel
comput
approach
rna
review
focus
small
molecul
ligand
molecular
weight
brief
mention
made
copperbind
metallopeptid
develop
target
domain
hcv
ire
damag
rna
metalcatalyz
cleavag
peptid
contain
conserv
acid
motif
glyglyhi
coordin
cu
link
recognit
sequenc
confer
rna
target
bind
specif
cumetallopeptid
amino
acid
report
bind
ire
domain
inhibit
hcv
cell
cultur
submicromolar
affin
program
ribosom
frameshift
evolutionari
strategi
maxim
code
content
genom
provid
mechan
allow
translat
overlap
read
frame
rna
virus
includ
hiv
sever
acut
respiratori
syndrom
cov
sar
cov
regul
transit
highli
express
structur
protein
viral
enzym
express
low
level
frameshift
translat
translat
frameshift
trigger
interplay
two
rna
motif
includ
slipperi
sequenc
read
frame
chang
occur
follow
structur
region
stall
ribosom
structur
frameshift
motif
hiv
consist
long
rna
hairpin
intern
loop
explor
ligand
target
approach
aim
stabil
disrupt
rna
fold
earlier
studi
hiv
target
discuss
recent
comprehens
review
le
grice
brakiergingra
cowork
sar
cov
translat
viral
protein
requir
replic
includ
rnadepend
rna
polymeras
initi
program
frameshift
trigger
threestem
rna
pk
figur
park
colleagu
use
silico
screen
approach
identifi
ligand
sar
cov
pk
sinc
threedimension
structur
target
determin
yet
dock
compound
perform
model
rna
pk
among
hit
compound
identifi
screen
druglik
deriv
mtdb
tabl
report
inhibitor
translat
frameshift
vitro
cellbas
assay
ic
direct
interact
sar
cov
pk
demonstr
recent
ritchi
cowork
measur
ligand
bind
rna
target
surfac
plasmon
reson
spr
determin
k
went
perform
singlemolecul
unfold
experi
pk
absenc
presenc
led
conclus
ligand
bind
reduc
conform
plastic
rna
fold
therebi
affect
ribosom
frameshift
effici
frameshift
determin
thermodynam
stabil
pk
impact
ribosom
paus
rather
abil
rna
fold
adopt
altern
conform
structur
therefor
ligand
bind
may
affect
translat
frameshift
complex
mechan
partial
reli
stabil
pk
rna
previous
identifi
inhibitor
hiv
translat
frameshift
suggest
promiscu
rnabind
abil
may
affect
ribosom
rna
rather
viral
genom
frameshift
signal
interact
multipl
target
may
play
role
inhibitori
action
well
may
account
higher
potenc
compound
frameshift
inhibitor
cellbas
assay
compar
rna
bind
affin
influenza
orthomyxoviru
harbor
singlestrand
rna
genom
contain
eight
negativesens
segment
vrna
encod
viral
protein
use
templat
transcript
mrna
replic
complementari
strand
crna
viral
rnadepend
rna
polymeras
recogn
partial
duplex
structur
form
circular
vrna
hybrid
conserv
nucleotid
end
segment
result
rna
duplex
figur
stabl
physiolog
condit
serv
promot
transcript
replic
investig
rna
promot
structur
nmr
reveal
bifurc
interact
uracil
base
hydrogen
bond
two
consecut
adenin
residu
opposit
strand
motif
conjunct
neighbor
noncanon
aoc
base
pair
induc
widen
major
groov
rna
promot
helix
near
polymeras
initi
site
sinc
uniqu
structur
featur
introduc
intern
loop
noncanon
base
pair
previous
shown
provid
ligand
recognit
site
duplex
rna
conceiv
select
compound
bind
influenza
rna
promot
might
interfer
polymeras
interact
prevent
viral
replic
inhibitor
interfer
viral
gene
express
bind
rna
promot
would
provid
novel
mechan
action
develop
antiinfluenza
drug
earlier
studi
choi
cowork
use
competit
assay
fluoresc
label
binder
box
test
aminoglycosid
bind
influenza
rna
promot
affin
low
micromolar
rang
k
report
variou
aminoglycosid
impact
ligand
bind
promot
function
investig
recent
varani
cowork
perform
nmrbase
fragment
bind
screen
compound
oligonucleotid
model
influenza
rna
promot
figur
among
seven
initi
hit
compound
led
chang
rna
imino
proton
signal
observ
nmr
druglik
aminoquinazolin
dpq
tabl
highest
affin
k
nmr
spectroscopi
use
obtain
model
promot
complex
figur
b
c
ligand
bind
observ
widen
rna
major
groov
intern
loop
form
bifurc
u
aa
motif
nmr
model
promot
complex
suggest
interact
rna
target
mainli
contact
methoxi
substitu
posit
close
residu
intern
loop
motif
figur
c
research
point
methoxi
group
proton
within
hydrogen
bond
distanc
hydrogen
bond
format
involv
carbonattach
donor
interact
oxygen
nitrogen
acceptor
unusu
preced
biomolecular
structur
interact
weak
may
rare
small
molecul
recognit
rna
fold
hydrogen
bond
involv
arylmethoxi
donor
observ
contribut
bind
ligand
crystal
structur
purin
riboswitch
sever
natur
product
antibiot
contain
arylmethoxi
group
includ
anisomycin
puromycin
crystal
structur
ribosomebound
complex
avail
howev
diffract
resolut
data
use
obtain
structur
limit
conclus
potenti
hydrogen
bond
interact
methoxi
group
emetin
antiprotozo
drug
bind
eukaryot
ribosom
contain
arylodimethoxyscaffold
compar
odimethoxyquinazolin
recent
cryoem
structur
plasmodium
ribosom
complex
emetin
show
arylmethoxi
group
solventexpos
orient
away
rna
howev
limit
resolut
cellbas
assay
measur
cytopath
effect
inhibit
demonstr
antivir
activ
rna
promotertarget
compound
strain
influenza
well
influenza
b
ec
valu
respect
cellbas
direct
viral
replic
assay
monitor
luciferas
report
express
modifi
influenza
viru
compound
inhibit
replic
ec
valu
time
cytotox
detect
compound
concentr
followup
studi
bottini
colleagu
synthes
test
analog
among
secondgener
aminoquinazolin
analog
set
four
structur
relat
compound
b
c
tabl
stood
improv
bind
affin
influenza
rna
promot
target
k
nmr
activ
inhibitor
viral
replic
ic
author
note
possibl
direct
inhibit
viral
rnadepend
rna
polymeras
aminoquinazolin
deriv
rule
yet
investig
none
compound
show
cytotox
maximum
test
concentr
virus
compact
highli
streamlin
genom
provid
limit
number
protein
target
therapeut
intervent
viral
infect
repertoir
drug
target
may
expand
target
structur
rna
element
genom
transcript
viral
pathogen
review
discuss
recent
progress
discoveri
small
moleculetarget
approach
direct
structur
rna
motif
genom
hiv
hcv
sar
cov
influenza
repres
varieti
viru
famili
regulatori
sequenc
viral
genom
transcript
stand
conserv
clinic
isol
promis
high
barrier
resist
develop
inhibitor
target
structur
rna
element
nevertheless
criteria
drugabl
thought
appli
select
rna
target
small
molecul
develop
novel
antivir
therapi
consider
import
ever
light
unpreced
surg
new
ncrna
speci
emerg
key
particip
biolog
process
structur
welldefin
deep
solventexclud
ligand
bind
pocket
rare
rna
fold
provid
promis
opportun
discoveri
druglik
inhibitor
par
drug
target
viral
protein
among
viral
rna
motif
discuss
hcv
ire
subdomain
iia
perhap
best
embodi
advantag
characterist
drug
target
also
uniqu
respect
function
conform
switch
harbor
proper
ligand
bind
pocket
similar
rna
switch
motif
discov
flaviand
picornavirus
howev
none
rise
level
threat
human
pathogen
compar
hcv
outsid
virus
compar
deepli
encapsul
ligand
bind
pocket
rna
found
bacteri
riboswitch
exploit
target
antibiot
discoveri
lesson
effort
ligand
discoveri
structur
rna
element
includ
regulatori
motif
virus
discuss
bacteri
rrna
riboswitch
ncrna
may
inspir
futur
search
inhibitor
target
rna
motif
wider
rang
humanpathogen
virus
tabl
list
select
virus
high
human
diseas
burden
structur
rna
element
shown
play
role
infect
insectborn
flavivirus
includ
dengu
west
nile
zika
virus
harbor
multiplestructur
rna
motif
involv
replic
translat
control
host
adapt
sever
flaviviru
rna
element
featur
conserv
structur
complex
compar
viral
rna
motif
discuss
review
may
tractabl
target
small
molecul
ligand
discoveri
varieti
potenti
drug
target
structur
rna
element
also
found
filovirus
includ
etiolog
agent
ebola
marburg
hemorrhag
fever
replic
negativesens
rna
virus
reli
structur
rna
promot
element
consist
larg
hairpin
involv
nucleotid
terminu
viral
genom
whose
secondari
structur
establish
chemic
probe
terminu
filoviru
genom
interact
end
unlik
rna
promot
influenza
viru
also
negativesens
ssrna
genom
filoviru
genom
consist
nonseg
rna
encod
read
frame
seven
structur
protein
separ
long
intergen
region
igr
igr
viru
protein
suggest
fold
twoarm
stemloop
structur
includ
complex
rna
fourway
junction
transcript
viral
gene
involv
nucleocapsid
protein
antitermin
factor
bind
hairpin
loop
transcript
start
site
viral
transcript
long
utr
element
deriv
igr
contain
hairpin
loop
structur
may
play
role
transcript
regul
translat
control
exampl
attract
rna
target
ligand
inhibit
also
found
dna
virus
among
oncogen
kaposi
sarcoma
associ
herpesviru
kshv
common
caus
malign
aid
patient
translat
viral
homolog
flice
inhibitori
protein
vflip
key
player
involv
kshvinduc
tumorigenesi
initi
ire
element
adopt
complex
rna
secondari
structur
includ
conserv
segment
nucleotid
function
chemic
probe
analysi
vflip
ire
reveal
independ
fold
rna
core
domain
link
flexibl
link
hairpin
motif
provid
sever
structur
welldefin
site
ligand
target
kshv
also
encod
nucleotid
polyadenyl
nuclear
pan
ncrna
abund
transcript
produc
viral
genom
lytic
replic
pan
rna
essenti
viral
propag
accumul
reli
posttranscript
stabil
involv
cisact
rna
motif
act
enhanc
nuclear
retent
element
ene
ene
nucleotid
motif
pan
terminu
sequest
ci
pan
poli
tail
uniqu
tripl
helix
structur
protect
ncrna
decay
lead
accumul
pan
ene
hairpin
structur
contain
uridinerich
larg
intern
loop
enepoli
tripl
helix
complex
potenti
target
small
molecul
ligand
may
interfer
kshv
replic
one
final
exampl
tractabl
rna
target
dna
viru
pregenom
rna
pgrna
hepat
b
viru
hbv
serv
intermedi
templat
viral
replic
revers
transcript
prior
revers
transcript
hbv
pgrna
sequest
togeth
polymeras
subvir
particl
encapsid
initi
revers
transcriptas
requir
conserv
sequenc
termin
region
pgrna
fold
stem
loop
structur
uridinerich
intern
loop
refer
epsilon
encapsid
signal
small
molecul
ligand
rna
motif
report
yet
rna
decoy
epsilon
sequenc
develop
sequest
revers
transcriptas
provid
proofofprincipl
disrupt
pgrnapolymeras
interact
suppress
hbv
replic
conclus
prevent
vaccin
drug
target
wellcharacter
viral
protein
polymeras
proteas
proven
rout
antivir
therapi
structur
rna
motif
viral
genom
transcript
provid
new
opportun
expand
repertoir
target
develop
antiinfect
therapi
select
viral
structur
rna
element
inhibitor
discoveri
requir
critic
evalu
properti
defin
target
druglik
ligand
protein
particip
key
player
diseas
process
unyield
develop
small
molecul
inhibitor
structur
rna
element
amen
target
low
molecular
weight
ligand
current
known
target
space
biolog
activ
small
molecul
natur
product
sourc
guidanc
rna
target
certainli
appear
among
low
hang
fruit
drug
discoveri
nevertheless
area
antiinfect
drug
provid
strong
record
success
exampl
rnadirect
inhibitor
bacteri
ribosom
target
half
natur
product
known
exhibit
antibiot
activ
major
compound
interact
predominantli
rrna
compon
bacteri
ribosom
loom
larg
paradigm
structur
rna
provid
valuabl
target
antiinfect
drug
recent
bacteri
riboswitch
rna
